Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0000950157-25-000586 0000875045 XXXXXXXX LIVE 2 Common Stock, par value $0.0001 per share 07/30/2025 true 0001597553 78667J108 Sage Therapeutics, Inc. 55 Cambridge Parkway Cambridge MA 02142 Wendell Taylor, Secretary (617) 679-2000 Biogen Inc. 225 Binney Street Cambridge MA 02142 0000875045 Biogen Inc. OO DE 0 0 0 0 0 N 0 CO Y Biogen MA Inc. OO MA 0 0 0 0 0 N 0 CO Common Stock, par value $0.0001 per share Sage Therapeutics, Inc. 55 Cambridge Parkway Cambridge MA 02142 The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned ("Amendment No. 2") on January 10, 2024, as amended by Amendment No. 1 on July 21, 2025. This Amendment No. 2 amends the Schedule 13D as specifically set forth herein. Item 5 is hereby amended and restated in its entirety as follows: As of July 28, 2025, the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons was 6,241,473.00 shares, representing 9.941% of the 62,784,397 issued and outstanding shares of Common Stock of the Issuer as of July 23, 2025 (as disclosed in the Issuer's most recent quarterly report on Form 10-Q filed on July 30, 2025). On July 29, 2025, the Reporting Persons sold all of their shares of Common Stock at a price per share of $8.53 in a block trade. As of the date of this filing, the Reporting Persons beneficially own no shares of Common Stock, representing 0.00% of the issued and outstanding shares of Common Stock. As of the date of this filing, the Reporting Persons have no powers to vote, or to direct the vote of, or to dispose, or to direct the disposition of, shares of Common Stock. Item 5(a) of this Schedule 13D is incorporated by reference into this Item 5(b). Item 5(a) of this Schedule 13D is incorporated by reference into this Item 5(c). Not applicable. On July 29, 2025, the Reporting Persons ceased to be the beneficial owners of more than five percent of Common Stock. Biogen Inc. /s/ Michael Dambach Michael Dambach / Treasurer 07/30/2025 Biogen MA Inc. /s/ Michael Dambach Michael Dambach / Treasurer 07/30/2025